Organic Active Ingredients TRIZ Cases

Merging orlistat and acarbose in a modified-release formulation reduces gastrointestinal side effects while improving body weight loss.

2-Oxo-1-pyrrolidinyl triazole derivatives modify molecular structures to counteract cognitive decline while reducing side effects.

Modified nucleotides enhance siRNA stability against degradation while maintaining potent silencing of the Notch 1 gene.

A polyamine-containing composition enables efficient transdermal iontophoretic delivery of cationic active agents.

Small molecule compounds disrupt Rev-RRE-Crm1 interactions to reduce HIV virion formation while managing design complexity.

Continuous torque monitoring during sol-gel processing controls particle size and distribution without visual phase separation checks.

A transfer tube routes medium from a lower canister outlet to an upper mouthpiece, resolving orientation-dependent discharge issues.

GDF6 protein and miR-17 family members reverse age-related deterioration by lowering inflammatory cytokines and promoting tissue regeneration.

A tavaborole preparation process uses boronic acid intermediates to isolate the active pharmaceutical ingredient.

AMD3100 blocks CXCR4 receptors to inhibit mesenchymal stem cell migration, alleviating tumor-induced tissue wasting and improving patient survival.

Ulipristal acetate maintains contraceptive efficacy across varying BMI ranges where levonorgestrel fails.

Liposomal encapsulation improves oral bioavailability of rose bengal disodium, resolving low drug concentration issues in pediatric leukemia treatment.

let-A IncRNA triggers rapid cell death in cancer cells by activating the Toll signaling pathway, addressing uncharacterized biological functions.

Macrocyclic structures improve brain permeability and safety while maintaining therapeutic efficacy for narcolepsy treatment.

Glucagon receptor antagonist compounds exhibit markedly longer half-lives through systematic molecular parameter changes.

Eliminating palladium catalysts removes metal contaminants from carbohydrate-conjugated iRNA synthesis, simplifying purification.

Stapled peptides target SNAI2 and SOX7 to block early viral replication, overcoming limited efficacy of late-stage polymerase inhibitors.

Midazolam inhibits VEGF-induced Ca2+ elevation and ROS generation, reducing vascular leakage without interfering with glycemic control.

Converting PAC-1 to amorphous form reduces neurotoxicity while maintaining anti-tumor efficacy for metastatic tumor treatment.

Administering tasimelteon immediate release prior to bedtime regulates circadian rhythms and improves total sleep time.

Micronized imatinib particles in high-API ratio formulations enable deep lung deposition via aerosolization.

STAT1 inhibitors block the CH25H axis to reduce amyloid beta deposition, addressing limited clinical effectiveness of current therapies.

Lactobacillus rhamnosus HN001 addresses limited treatment options during pregnancy by reducing eczema prevalence via specific strain administration.

Targeting Connexin 45 with nucleic acid inhibitors reduces QRS prolongation, avoiding pro-arrhythmic side effects of conventional drugs.

Selective N-butylation avoids methansulfonylation impurities, achieving high purity and yield while simplifying synthesis.

Macrocyclic 2-amino-but-3-enamides block MCL-1 anti-apoptotic functions to overcome therapy resistance in cancers like leukemia and melanoma.

A crystalline potassium salt of ascorbic acid 2-glucoside forms via alcohol precipitation from an aqueous solution.

Transmucosal artemether spray bypasses gastrointestinal issues to ensure reliable bioavailability in children.

Selective tryptophan hydroxylase 1 inhibition reduces peripheral serotonin synthesis while sparing central nervous system pathways.

Measuring myeloid-derived suppressor cell ratios identifies patients for entinostat combination therapy.

Chemically sulphated hyaluronic acid maintains cartilage structural integrity through targeted intra-articular administration.

Controlled moisture content balances mechanical strength and solubility, preventing weight variation during direct compression of tobacco tablets.

Combining CXCR4 antagonists with STAT3 activators bridges nerve gaps exceeding 3 cm, restoring sensory and motor function.

Intra-cyclic peroxo-bridged sesquiterpene compounds regulate liver cell mitochondria to enhance fatty acid beta-oxidation capacity.

StIR compositions stimulate innate immune resistance in lungs using Toll-like receptor agonists to enhance biological defenses against pathogens.

Non-glycosylated flavone cirsimaritin promotes healing in diabetic wounds by neutralizing free radicals and inhibiting inflammatory mediators.

Pyrido[2,3-d]pyrimidin-4-amine compounds selectively inhibit the Ras-Sos1 interaction to treat hyperproliferative disorders with reduced skin toxicity.

Segmented peptides inhibit TRPV6 channels without paralytic activity, reducing tumor volume while maintaining solubility.

Aggregating participant sensor data to fill coverage gaps, reducing bandwidth waste from overlapping signals while maintaining complete air traffic safety.

siRNA compositions target mutant PNPLA3 alleles to reduce hepatic triglyceride accumulation.

2′-Spirothietane nucleosides target conserved viral polymerase regions, overcoming genetic heterogeneity in HCV and dengue treatments.

Formula I pyrimidinone derivatives inhibit Cdc7 kinase, exploiting checkpoint defects to kill cancer cells while sparing normal tissue.

Targeting tumor-associated stromal antigens overcomes limited efficacy of traditional tumor cell antigens by reducing tumor growth and vascularization.

Beta-1,3-glucan from Euglena reduces cholesterol and triglyceride levels while enhancing anti-inflammatory cytokine production.

A topical pharmaceutical composition delivers a potent cPLA2 inhibitor directly to the skin.

Ligating shRNA duplexes to ACE2 polypeptides enables targeted delivery of gene-silencing agents to infected cells while neutralizing viral RBDs.